| Summary: | 碩士 === 輔仁大學 === 企業管理學系管理學碩士在職專班 === 106 === The global biotechnology and pharmaceutical industry are now blooming. However, the ecology of the pharmaceutical industry and the market share of pharmaceuticals are constantly affected by many factors in various countries due to different insurance systems. Couple with Taiwan's unique national health insurance system and complex relationship between the medical and disease culture and the characteristics of the marketing culture, the domestic drug access pattern remains unchanged, with the market transaction mechanism being continuously integrated, the Central Health Insurance Department has become the largest buyer in the pharmaceutical market and has dominated the overall pharmaceutical market, which has affected the development of drug sales channels. Therefore, in the context of this environment, the business strategy of Taiwan's pharmaceutical industry often needs to follow the government's ordinance to amend and respond to adjustments. It is therefore necessary to construct a strategy with competitive advantage, and consider transformation to protect its competitive advantage.
The qualitative research method of this study was conducted through expert in-depth interviews, secondary data analysis, and Internet-related research on industry-related literature to analyze the success factors of Taiwan's pharmaceutical industry in achieving competitive advantage. Due to small business scale in Taiwan and relatively more fierce competition, case companies need to adopt differentiated strategies. The ability to improve the quality of pharmaceutical products is in line with the government's regulatory requirements for pharmaceutical plants cGMP. It is necessary to have excellent systematic human resources management to achieve a considerable economic scale in the production of drugs in order to effectively reduce costs and increase the profitability of the company.
Given the health care environment in Taiwan, the entire Taiwanese pharmaceutical market is facing severe challenges. It is hoped that this research will provide domestic pharmaceutical manufacturers with an advantageous market competition strategy and decision making reference for transformation. The results can also serve as the basis for further in-depth study of the western medicine industry in Taiwan and will contribute to the commercial development of this industry。
|
|---|
